M. Wang 2024 EHA Poster: A Multi-Center, Open-Label, Phase 1/2 Study of ONCT-808, A ROR1-Targeting CAR T Cell Therapy, in Adults with Relapsed/Refractory Aggressive B Cell Lymphomas